Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio
Neurocrine Biosciences (NasdaqGS:NBIX) held an M&A call to discuss a potential transaction with Soleno Therapeutics, signaling a move to broaden its portfolio beyond existing products like INGREZZA and CRENESSITY. This potential acquisition could add new drug candidates, especially in rare diseases or niche CNS programs, diversifying revenue and therapeutic areas. Investors are advised to monitor the deal's details, including its impact on Neurocrine's financial position, research focus, and long-term growth strategy.
Robinhood Asset Management LLC Makes New $5.72 Million Investment in Neurocrine Biosciences, Inc. $NBIX
Robinhood Asset Management LLC has initiated a new position in Neurocrine Biosciences, Inc. (NBIX), acquiring 40,296 shares valued at approximately $5.72 million in the fourth quarter. This comes amidst mixed analyst reactions to Neurocrine's recent acquisition of Soleno Therapeutics for $2.9 billion, designed to expand its commercial footprint and diversify revenue, despite missing Q4 earnings estimates. CEO Kyle Gano also reduced his stake by selling shares worth $4.83 million, though institutional investors and hedge funds still collectively own 92.59% of the company.
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
Neurocrine Biosciences (NBIX) is transitioning from a single-product success with Ingrezza to a diversified neuroscience and endocrinology powerhouse. This shift is driven by aggressive pipeline development, including the recently approved Crenessity, and strategic M&A, highlighted by the $2.9 billion acquisition of Soleno Therapeutics, which brings Vykat XR into its portfolio. The company's future growth hinges on the successful integration of its new acquisitions and positive Phase 3 readouts for its muscarinic M4 selective agonist for schizophrenia in early 2027.
This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition
Neurocrine Biosciences is set to acquire Redwood City-based Soleno Therapeutics for $2.9 billion, a significant turnaround for a company whose stock had previously fallen below $1. This acquisition highlights the impact of a community-driven effort by parents of children with a rare genetic disorder who championed the company's drug development. The deal underscores a remarkable recovery for Soleno Therapeutics, culminating in a $53-a-share acquisition.
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster
Neurocrine Biosciences has announced the acquisition of Soleno Therapeutics for $2.9 billion. The deal, funded by cash and modest debt, is expected to be immediately accretive in 2026. Neurocrine anticipates Vykat XR, Soleno's newly launched drug for Prader-Willi syndrome, to achieve "blockbuster potential" given its validated market and anticipated exclusivity.
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion in cash, marking Neurocrine's entry into the metabolic disease drug market. Soleno recently received approval for a drug treating Prader-Willi syndrome, a rare genetic disease causing extreme hunger. This acquisition offers a significant premium to Soleno shareholders and diversifies Neurocrine's drug portfolio.
Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal
Neurocrine Biosciences (NASDAQ:NBIX) is set to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash deal worth approximately $2.9 billion, paying $53 per share for Soleno. This acquisition primarily targets Soleno's drug VYKAT XR, approved in 2025 for hyperphagia associated with Prader-Willi syndrome, a condition affecting an estimated 10,000 Americans. Neurocrine aims to expand the therapy's reach and strengthen its position in endocrinology and rare diseases.
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, significantly expanding its commercial portfolio in endocrinology and rare diseases. The deal centers on Soleno’s drug Vykat XR, approved in 2025 for extreme hunger in Prader-Willi syndrome patients. Despite the 51% premium offered, analysts at Stifel expressed surprise at Soleno's acceptance, given the strong growth potential predicted for Vykat XR, which had already generated $190.4 million in sales for 1,250 patients in under a year.
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Neurocrine Biosciences announced its intent to acquire Soleno Therapeutics for $2.9 billion. The deal involves Neurocrine paying $53 per share for Soleno, representing a 34% premium. Soleno's drug, Vykat, approved in March 2025, treats hyperphagia associated with the rare genetic disorder Prader-Willi syndrome.
Neurocrine to Buy Soleno Therapeutics for $2.9 Billion
Neurocrine Biosciences Inc. has agreed to acquire Soleno Therapeutics Inc. for $2.9 billion. This acquisition aims to secure access to Soleno's drug for a rare disorder characterized by insatiable appetites. Neurocrine will pay $53 per share, representing a 34% premium, using cash and debt, with the transaction expected to close within 90 days.
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Neurocrine Biosciences has announced its definitive agreement to acquire Soleno Therapeutics for $2.9 billion, or $53.00 per share in cash. This acquisition will add VYKAT XR, a first-in-class treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio, enhancing its leadership in endocrinology and rare diseases. The deal is expected to accelerate revenue growth, diversify Neurocrine's offerings, and leverage VYKAT XR's strong intellectual property, which extends into the mid-2040s.
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion in cash, marking its entry into metabolic disorders. This deal gives Neurocrine access to Vykat XR, a drug for Prader-Willi syndrome's hyperphagia, bolstering its rare-disease portfolio. The acquisition is expected to close within 90 days and will be funded by cash on hand and modest prepayable debt.
Nisa Investment Advisors Reduces Neurocrine Biosciences Stake
Nisa Investment Advisors LLC significantly reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 80.8% in the fourth quarter of 2025, selling 21,945 shares. The institutional investor now owns 5,201 shares worth approximately $738,000. While the specific reasons for this portfolio adjustment were not disclosed, it could indicate a shift in investor sentiment or strategy concerning the biopharmaceutical company's future.
Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX
Nisa Investment Advisors LLC significantly reduced its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 80.8% in Q4, selling 21,945 shares and holding 5,201 shares valued at $738,000. Additionally, CEO Kyle Gano sold 36,400 shares for $4.83 million, decreasing his ownership by over 20%. Despite missing EPS estimates, Neurocrine Biosciences' Q4 revenue beat expectations, leading analysts to maintain an average "Moderate Buy" rating with a target price of $175.10.
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data In Older Tardive Dyskinesia Patients
Neurocrine Biosciences (NBIX) shared new data for its INGREZZA treatment in older tardive dyskinesia patients at the PALTC26 conference. The stock has seen a 28% total shareholder return over the past year, but recent momentum has cooled. While a narrative fair value suggests the stock is undervalued at $178.04 compared to its current price of $131.60, its P/E ratio of 27.6x is higher than peers and the industry average, indicating potential pricing pressure and limited room for growth disappointments.
Should You be Optimistic on Neurocrine Biosciences (NBIX)?
This article analyzes whether investors should be optimistic about Neurocrine Biosciences (NBIX). It would likely discuss the company's financial performance, drug pipeline, market position, and future growth prospects to provide a comprehensive outlook for potential investors.
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data In Older Tardive Dyskinesia Patients
Neurocrine Biosciences recently presented new data on its INGREZZA treatment for tardive dyskinesia in older adults at the PALTC26 conference. Despite a 28% total shareholder return over the past year, the company's valuation of US$131.60 per share suggests it is 26.1% undervalued compared to a narrative-based fair value of US$178.04, driven by its broad pipeline and innovation. However, its current P/E ratio of 27.6x is higher than peers, indicating potential pricing pressure and concentration risk.
8,437 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Nilsine Partners LLC
Nilsine Partners LLC recently acquired 8,437 shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) valued at approximately $1.197 million in the fourth quarter. This acquisition comes as other institutional investors have also adjusted their holdings in the biopharmaceutical company. Despite an EPS miss in its last quarterly report, analysts maintain a "Moderate Buy" rating for NBIX with an average target price of $175.10.
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC reduced its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 11.2% in Q4, selling over 43,000 shares. This comes as CEO Kyle Gano also sold a significant portion of his shares in January. Despite missing quarterly EPS estimates, Neurocrine's revenue grew by 28.3%, and analysts maintain a "Moderate Buy" consensus rating for the stock.
What Neurocrine Biosciences (NBIX)'s New Senior TD Data and Guidelines Could Mean For Shareholders
Neurocrine Biosciences presented new data and recommendations for its drug INGREZZA for older adults with tardive dyskinesia, highlighting its differentiated clinical profile in long-term care settings. While these developments support INGREZZA's role, particularly given the drug's sales guidance of US$2,700 million to US$2,800 million for 2026, investors should still consider potential risks from Medicare scrutiny and pricing pressures. The company's future investment narrative projects $4.2 billion revenue by 2029, suggesting a 35% upside to its current price according to some analysts.
What Neurocrine Biosciences (NBIX)'s New Senior TD Data and Guidelines Could Mean For Shareholders
Neurocrine Biosciences recently presented new expert consensus recommendations and INGREZZA (valbenazine) data for older adults with tardive dyskinesia, highlighting its differentiated clinical profile for seniors. This new information aims to support INGREZZA's role as a durable cash generator for Neurocrine, amidst ongoing pipeline maturation and potential pricing pressures. Investors will be observing how effectively these recommendations translate into real-world prescribing and sustained coverage, as the company projects significant revenue and earnings growth by 2029.
NBIX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Neurocrine Biosciences Inc (NBIX) as of March 31, 2026. It indicates a "Buy" consensus based on various technical indicators and moving averages, despite some sell signals from specific metrics. The analysis details key support and resistance levels, momentum indicators like RSI and MACD, and performance relative to different moving averages.
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics
Neurocrine Biosciences, Inc. has seen its stock decline to $128.32, with recent technical indicators suggesting a bearish trend despite a strong long-term performance. The company has delivered a 263.20% return over the past decade, significantly outperforming the S&P 500, showcasing its resilience amidst current market dynamics.
Neurocrine Biosciences Inc (NBIX) Shares Down 3.14% on Mar 30
Neurocrine Biosciences Inc (NBIX) shares dropped 3.14% on March 30, trading at $128.30 after touching an intraday low of $128.02. This price is 19.90% below its 52-week high but 52.32% above its 52-week low. Wall Street analysts maintain an "Outperform" rating with an average target price of $176.27, suggesting a potential upside of 37.39%, while GuruFocus estimates a GF Value of $207.07.
NBIX SEC Filings - Neurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms
This page provides access to Neurocrine Biosciences Inc. (NBIX) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4). It also features AI-powered summaries to help investors quickly understand key financial and corporate developments, such as recent financial results and insider transactions.
Wealth Enhancement Advisory Services LLC Boosts Stake in Neurocrine Biosciences, Inc. $NBIX
Wealth Enhancement Advisory Services LLC increased its stake in Neurocrine Biosciences by 33.1% in Q4 2025, now owning 54,393 shares valued at approximately $7.49 million. This occurred despite CEO Kyle Gano selling a significant portion of his shares. The company has an average "Moderate Buy" analyst rating with a target of $175.10, though it missed Q4 EPS estimates while revenue grew by 28.3%.
NBIX SEC Filings - Neurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms
This page serves as a comprehensive resource for Neurocrine Biosciences (NBIX) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. It provides direct access to regulatory disclosures, financial performance, and key corporate developments, with AI-powered summaries to highlight important points. The page also details recent insider transactions and major ownership disclosures.
Free cash flow per share of Neurocrine Biosciences, Inc. – DUS:NB3
This article displays the free cash flow per share for Neurocrine Biosciences, Inc. (DUS:NB3). It presents a table with periods, values, and percentage changes related to the free cash flow, but the table itself is not populated with data in this provided content. The page also includes standard financial market data disclaimers and copyright information for various data providers.
Nordea Investment Management AB Increases Stake in Neurocrine Biosciences, Inc. $NBIX
Nordea Investment Management AB significantly increased its stake in Neurocrine Biosciences, Inc. (NBIX) by 81.3% in Q4 2025, bringing their total holdings to 27,202 shares valued at $3.83 million. Institutional investors now own 92.59% of the company, with other major holders including Dodge & Cox, JPMorgan Chase & Co., AQR Capital Management LLC, and Norges Bank. Despite missing EPS expectations in the latest quarter, Neurocrine Biosciences reported strong revenue growth of 28.3% year-over-year, and analysts maintain a "Moderate Buy" rating with an average price target of $175.10.
SG Americas Securities LLC Buys 119,339 Shares of Neurocrine Biosciences, Inc. $NBIX
SG Americas Securities LLC significantly increased its stake in Neurocrine Biosciences, Inc. during the fourth quarter, purchasing 119,339 additional shares. This brought their total holdings to 134,530 shares, valued at approximately $19.08 million. Neurocrine Biosciences reported mixed Q4 earnings, with revenue slightly above estimates but EPS missing expectations, and the stock currently holds a "Moderate Buy" consensus rating from analysts.
Assenagon Asset Management S.A. Has $11.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX
Assenagon Asset Management S.A. significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 70.4% in Q4, with its holdings now valued at approximately $11.35 million. This comes as institutional interest in NBIX is high, though CEO Kyle Gano recently sold a portion of his shares. Analysts generally maintain a "Moderate Buy" rating for Neurocrine Biosciences, despite a recent earnings per share miss.
[SCHEDULE 13G/A] NEUROCRINE BIOSCIENCES INC Amended Passive Investment Disclosure
The Vanguard Group filed an Amendment No. 10 to its Schedule 13G/A for Neurocrine Biosciences Inc. (NBIX), reporting 0% beneficial ownership due to an internal realignment effective January 12, 2026. This change means Vanguard subsidiaries will now report holdings separately. The filing clarifies this is an administrative reporting shift, not a market trade, and advises investors to monitor future filings from individual Vanguard entities for ownership updates.
Tudor Investment Corp ET AL Buys 23,893 Shares of Neurocrine Biosciences, Inc. $NBIX
Tudor Investment Corp significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) during Q3, purchasing 23,893 shares to own 26,860 shares valued at $3.77 million. Other institutional investors like AQR and JPMorgan Chase also boosted their positions, contributing to 92.59% institutional ownership, while CEO Kyle Gano reduced his insider holdings by 20.59%. Despite missing Q earnings estimates with an EPS of $1.88 versus $2.36 expected, the company reported $805.5M in revenue and holds a "Moderate Buy" consensus rating with a $175.10 target price.
Is Geriatric-Focused INGREZZA Data Quietly Reframing Neurocrine Biosciences' Neurology Leadership Narrative (NBIX)?
Neurocrine Biosciences recently presented new data for INGREZZA focused on its use in older adults with tardive dyskinesia, alongside expert recommendations for treatment in long-term care settings. This move aims to enhance INGREZZA's clinical relevance in the geriatric population and reinforce Neurocrine's neurology leadership. While positive, the article suggests that near-term investment in Neurocrine continues to be influenced by payer dynamics and pricing pressure, despite long-term growth projections and strategic investments in broader drug modalities.
Neurocrine Biosciences Updates Tardive Dyskinesia Care And Valuation Story
Neurocrine Biosciences (NasdaqGS:NBIX) has strengthened its position in tardive dyskinesia care by releasing new expert recommendations for older adults and reporting positive INGREZZA clinical data for this demographic. The company also appointed a Chief Technical Operations Officer to enhance manufacturing capabilities. Investors are presented with updated clinical insights and operational leadership, which could influence capital allocation, while the stock currently trades below analyst expectations and estimated fair value.
NBIX SEC Filings - Neurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Neurocrine Biosciences Inc. (NBIX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material event forms. It details recent financial results, executive transactions, and ongoing developments for the biopharmaceutical company, with AI-powered summaries to highlight key information. The article also provides a recent stock price and market capitalization for NBIX.
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Neurocrine Biosciences announced the presentation of the first expert consensus recommendations for tardive dyskinesia in older adults within long-term care settings. These recommendations, developed by a multidisciplinary Delphi panel, aim to address existing gaps in the screening, diagnosis, and treatment of tardive dyskinesia among this high-risk population. The findings were unveiled at the Society for Post-Acute and Long-Term Care Medical Association (PALTmed) PALTC26 Annual Conference.
NBIX SEC Filings - Neurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms
This page provides access to Neurocrine Biosciences (NBIX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K current event reports. It highlights recent filings detailing financial results, executive changes, and insider trading activity, and offers AI-powered summaries for quicker insights. The platform aims to help investors analyze the company's financial performance, risk factors, and strategic developments.
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Neurocrine Biosciences has announced the first expert consensus recommendations for the screening, diagnosis, and treatment of tardive dyskinesia (TD) in older adults within long-term care settings, developed through a multidisciplinary Delphi panel. Concurrently, new post-hoc analysis from the KINECT-PRO™ study demonstrated significant patient-reported improvements in TD impact among adults aged 65 and older treated with INGREZZA® (valbenazine) capsules, reinforcing the expert panel's recommendations. These initiatives aim to address existing gaps in managing TD in this vulnerable population and provide structured guidance for clinicians.
Neurocrine Biosciences Inc (NBIX) Shares Up 3.53% on Mar 25
Neurocrine Biosciences Inc (NBIX) shares rose 3.53% on March 25, closing at $132.37. This places the stock significantly above its 52-week low, though still below its 52-week high. Analysts forecast an average price target of $176.27, suggesting substantial upside, and the company holds an "Outperform" recommendation from brokerage firms.
CIBC Private Wealth Group LLC Grows Stock Position in Neurocrine Biosciences, Inc. $NBIX
CIBC Private Wealth Group LLC significantly increased its stake in Neurocrine Biosciences (NASDAQ: NBIX) by 17,250% in the third quarter of 2025, now holding 7,981 shares valued at $1.12 million. Despite this, Neurocrine Biosciences missed Q3 EPS expectations, reporting $1.88 against an estimated $2.36, although revenue saw a 28.3% year-over-year increase. The article also notes that institutional investors own a substantial 92.59% of the company, and highlights recent insider stock sales by CEO Kyle Gano.
Neurocrine Biosciences, Inc. - Common Stock (NQ: NBIX)
This article provides a compilation of recent news headlines regarding Neurocrine Biosciences, Inc. (NASDAQ: NBIX). The news covers a range of topics including Q4 earnings reports, analyst perspectives, stock performance, and drug development updates, offering insights into the company's financial health, growth potential, and product pipeline.
CIBC Private Wealth Group Boosts Neurocrine Biosciences Stock Holdings
CIBC Private Wealth Group LLC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) during the third quarter of 2025, boosting its holdings by 17,250% to 7,981 shares valued at $1.12 million. This move reflects growing confidence in Neurocrine Biosciences' pipeline of neurological and endocrine disorder treatments. The investment firm is a subsidiary of Canadian Imperial Bank of Commerce.
Assessing Neurocrine Biosciences (NBIX) Valuation As Shares Soften Despite Growing Revenue And Net Income
Neurocrine Biosciences (NBIX) shares have softened recently, down 13% over three months and 9% year-to-date, despite positive annual revenue and net income growth. The stock's fair value is estimated at $179.59, suggesting it is undervalued, driven by a strong pipeline and innovation. However, its current P/E ratio of 26.8x is higher than industry averages, indicating potential valuation risk if growth expectations abate.
Assessing Neurocrine Biosciences (NBIX) Valuation As Shares Soften Despite Growing Revenue And Net Income
Neurocrine Biosciences (NBIX) has seen its shares soften recently despite growth in revenue and net income. While the stock's short-term momentum is down, longer-term returns remain positive. The company's fair value is estimated to be 28.9% higher than its current share price, driven by a strong pipeline and internal innovation, although its P/E ratio is higher than industry averages, indicating potential valuation risk if growth expectations diminish.
Assessing Neurocrine Biosciences (NBIX) Valuation As Shares Soften Despite Growing Revenue And Net Income
Neurocrine Biosciences (NBIX) shares have softened recently, down 13% over three months and 9% year-to-date, despite positive annual revenue and net income growth. The stock is currently valued at $127.68, with a "most popular narrative" suggesting a fair value of $179.59, indicating it might be undervalued by 28.9%. However, its P/E ratio of 26.8x is higher than industry averages, posing a valuation risk if growth expectations diminish.
If You Invested $1,000 in Neurocrine Biosciences Inc (NBIX)
This article examines the historical performance of a hypothetical $1,000 investment in Neurocrine Biosciences Inc (NBIX) over different periods, showing its total return and Compound Annual Growth Rate (CAGR). It also provides a detailed overview of Neurocrine Biosciences, including its therapeutic focus, core commercial products like INGREZZA and CRENESSITY, its research and development pipeline for various neurological and endocrine disorders, and key financial information. The company's performance is also compared against the S&P 500.
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP significantly reduced its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 47.8% in Q3, selling 37,083 shares. Despite the company missing EPS estimates, its revenue grew by 28.3% year-over-year, and analysts maintain a "Moderate Buy" rating with an average price target of $175.10. Additionally, CEO Kyle Gano sold 36,400 shares, decreasing his position by 20.59%.
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2026 Virtual CNS Forum, Mar-17-2026 04
Neurocrine Biosciences, Inc. presented at the Stifel 2026 Virtual CNS Forum on March 17, 2026. The presentation included remarks from CEO Kyle Gano and Head of IR Todd Tushla, moderated by analyst Paul Matteis. The full transcript of this presentation is exclusively available to subscribers.
Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants
Neurocrine Biosciences' Chief Technical Operations Officer, Andrew Ratz, has reported his initial equity holdings via a Form 3 SEC filing. The filing details his direct ownership of 1,018 shares of common stock, along with significant grants of restricted stock units and incentive/non-qualified stock options. These awards are subject to vesting schedules through 2029, 2030, 2035, and 2036, representing potential future ownership in the company.
